ChemRar Group successfully completed contracts for the Federal Program “Development of the Pharmaceutical and Medical Industry of the Russian Federation for 2013–2020”:

— The project: “Transfer of foreign developments for an innovative drug that is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus for treatment of HIV/AIDS, and its preclinical and clinical studies”.
— The project: “Transfer of foreign developments for an innovative drug that is an NS5A protein inhibitor of the hepatitis C virus for the treatment of hepatitis C, and its preclinical and clinical studies”.
— The project: “Organization and clinical trials of a drug that is a serotonin receptor inhibitor for the treatment of schizophrenia”.
— The project: “Preclinical studies of neuraminidase inhibitors for the treatment of influenza that are effective in strains resistant to the existing drugs”.
— The project: “Transfer of foreign developments for drugs based on a histone deacetylase inhibitor for the treatment of cancer, and their preclinical and clinical studies”.
— The project: “Transfer of foreign developments for an innovative combination product with a synergistic action of components on the level of the enteroendocrine hormones for the treatment of type 2 diabetes and obesity, and its preclinical and clinical studies”.
— The project: “Transfer of foreign developments for drugs based on factor X inhibitors for the treatment of thrombosis, and their preclinical and clinical studies”.